Back to Search
Start Over
Treatment Failure With Rhythm and Rate Control Strategies in Patients With Atrial Fibrillation and Congestive Heart Failure: An AF-CHF Substudy
- Source :
- Journal of Cardiovascular Electrophysiology. 26:1327-1332
- Publication Year :
- 2015
- Publisher :
- Wiley, 2015.
-
Abstract
- Treatment Failures in AF-CHF Introduction Rate and rhythm control strategies for atrial fibrillation (AF) are not always effective or well tolerated in patients with congestive heart failure (CHF). We assessed reasons for treatment failure, associated characteristics, and effects on survival. Methods and Results A total of 1,376 patients enrolled in the AF-CHF trial were followed for 37 ± 19 months, 206 (15.0%) of whom failed initial therapy leading to crossover. Rhythm control was abandoned more frequently than rate control (21.0% vs. 9.1%, P < 0.0001). Crossovers from rhythm to rate control were driven by inefficacy, whereas worsening heart failure was the most common reason to crossover from rate to rhythm control. In multivariate analyses, failure of rhythm control was associated with female sex, higher serum creatinine, functional class III or IV symptoms, lack of digoxin, and oral anticoagulation. Factors independently associated with failure of rate control were paroxysmal (vs. persistent) AF, statin therapy, and presence of an implantable cardioverter–defibrillator. Crossovers were not associated with cardiovascular mortality (hazard ratio [HR] 1.11 from rhythm to rate control; 95% confidence interval [95% CI, 0.73–1.73]; P = 0.6069; HR 1.29 from rate to rhythm control; 95% CI, 0.73–2.25; P = 0.3793) or all-cause mortality (HR 1.16 from rhythm to rate control, 95% CI [0.79–1.72], P = 0.4444; HR 1.15 from rate to rhythm control, 95% [0.69, 1.91], P = 0.5873). Conclusions Rhythm control is abandoned more frequently than rate control in patients with AF and CHF. The most common reasons for treatment failure are inefficacy for rhythm control and worsening heart failure for rate control. Changing strategies does not impact survival.
- Subjects :
- Creatinine
medicine.medical_specialty
Digoxin
business.industry
Hazard ratio
Atrial fibrillation
030204 cardiovascular system & hematology
medicine.disease
Confidence interval
3. Good health
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Rhythm
chemistry
Physiology (medical)
Heart failure
Internal medicine
Heart rate
medicine
Cardiology
030212 general & internal medicine
Cardiology and Cardiovascular Medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 10453873
- Volume :
- 26
- Database :
- OpenAIRE
- Journal :
- Journal of Cardiovascular Electrophysiology
- Accession number :
- edsair.doi...........71d9cf578cbbeeff179793669c1e9c7e